Your search returned 2 results.

Sort
Unhighlight Highlight
Select all Clear all
Select titles to:
Results
1.
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 27284114
Year: 2016
Citation:
  • Diabetes Care. 39(9):1579-86, 2016 Sep
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
DOI:
Add to cart
2.
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 28386990
Year: 2017
Citation:
  • Diabetes, Obesity & Metabolism. 19(10):1408-1415, 2017 Oct.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Bergenstal RM, Bonadonna RC, Kapitza C, LixiLan-L trial investigators, Niemoeller E, Puig-Domingo M, Souhami E, Stager W, Wysham C, Yu C
DOI:
Add to cart
Pages

Powered by Koha